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Abstract
Background: Corneal collagen crosslinking (CXL) is a widely used treatment for halting the progression of
keratoconus. Although initial studies of CXL were performed with a riboflavin solution containing dextran, recent
protocols for CXL have indicated the use of a riboflavin solution containing isotonic hydroxypropyl methylcellulose
(HPMC). This study was performed to investigate differences in visual outcomes and Scheimpflug (Pentacam)
analysis in patients who have undergone epithelium-off CXL with riboflavin solution containing either 20% dextran
versus 1.1% HPMC.
Methods: All patients in this non-randomized, non-masked, retrospective cohort analysis were treated at Edward S.
Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA. Thirty-seven eyes of 33 patients
were crosslinked with a dextran solution and 19 eyes of 19 patients crosslinked with an isotonic HPMC solution,
both using an epithelium-off 30-min, 3 mW/cm2 protocol. All patients had a diagnosis of keratoconus or post-
refractive surgery ectasia. Best spectacle corrected visual acuity (BSCVA) and Pentacam parameters were compared
at all follow up visits (1, 6, 12, and 24 months). Differences between groups treated with HPMC and dextran were
compared using student’s t-test. Differences between treated eye and fellow eye were calculated and compared
between HPMC and dextran groups using paired t-test.
Results: Patients treated with a dextran solution had significantly greater improvement in BSCVA at 1, 6, and
24 months (p < 0.05) compared to the isotonic HPMC-treated group. Kmax increased in both groups at 1 month;
however, HPMC-treated patients had a greater increase compared to dextran-treated patients (p = 0.01). Kmax
decreased in both groups at 6 and 12 months, although this finding was only significant in the HPMC-treated
group at 12 months.
Conclusions: Our data suggest that crosslinking with the dextran solution may result in significantly better visual
outcomes (demonstrated by visual acuity) compared to the isotonic HPMC riboflavin solution. Dextran solutions
may have other potential advantages intrinsic to its biochemical properties facilitating more efficient crosslinking.
Further research and long-term evidence regarding the use of dextran versus HPMC riboflavin solutions in collagen
crosslinking is necessary.
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Background
Keratoconus (KCN) is a condition characterized by thin-
ning of the corneal stroma and progressive deformation
of the cornea to a conical shape. Corneal collagen cross-
linking (CXL) is an evolving therapy shown to be effect-
ive in halting the progression of keratoconus and
post-refractive surgery ectasia [1–7].
The CXL procedure consists of photosensitizing the
cornea with a riboflavin solution and irradiating the cor-
nea with UVA light [1]. CXL to stop the progression of
KCN and post-refractive surgery ectasia has recently
been approved by the United States Food and Drug Ad-
ministration (FDA) using a 0.154% riboflavin in 20%
dextran solution.
One obstacle in evaluating the potential efficacy of
CXL is the variation in composition of the riboflavin so-
lutions that are in use. Both HPMC- and dextran-based
riboflavin solutions are widely used with a recent prefer-
ence being shown for HPMC solutions, possibly because
they do not cause thinning of the corneal stroma [8]. Al-
though many of the early trials showing the efficacy of
CXL were performed with a dextran-based riboflavin so-
lution, more recent studies frequently use HPMC-based
riboflavin solutions. Although there are proposed bene-
fits of CXL with HPMC, there is a dearth of published
data providing justification for the switch in common
use from dextran to HPMC.
Proposed benefits of an HPMC-based riboflavin solu-
tion compared to a dextran-based solution include ab-
sence of intraoperative corneal thinning [8–11],
increased diffusion rate [12], and convenience of use [10,
13]. These advantages primarily focus on intraoperative
effects of HPMC-based and dextran-based riboflavin so-
lutions. However, to our knowledge, there has been no
published data comparing clinical outcomes between
CXL with different isotonic solutions.
This study is a retrospective cohort analysis comparing
clinical outcomes in patients with progressive keratoco-
nus or post-refractive surgery ectasia who were treated
with CXL with a dextran-based or HPMC-based ribofla-
vin solution. All other treatment variables were identical.
Methods
The study protocol was approved by the Columbia Uni-
versity Institutional Review Board in accordance with
the Declaration of Helsinki and was Health Insurance
and Portability Accountability Act (HIPAA) compliant.
Study subjects completed the study procedure between
September 2010 and August 2015.
Study subjects
Eligible subjects were 18 years of age or older and signed
a written informed consent. Subjects with a diagnosis of
keratoconus had one or more of the following: (1)
presence of central or inferior steepening on the Pentacam
tomography map (Oculus Inc., Arlington, WA, United
States), (2) axial topography consistent with keratoconus,
(3) presence of Fleischer ring, Vogt striae, corneal thin-
ning, or corneal scarring. Progressive disease defined by
one of the following in the past 24 months or less: (1) in-
crease of > 1 diopter (D) in the steepest keratometry value
(Kmax) or astigmatism evaluated by subjective manifest
refraction, (2) documented decrease in visual acuity asso-
ciated with irregular astigmatism.
Patients with a diagnosis of post-refractive surgery
ectasia had disease defined by history of keratorefractive
surgery and two of the following: (1) steepening on cor-
neal topography, (2) thinning of the cornea, (3) shift in
position of the thinnest portion of the cornea, (4) devel-
opment of myopic astigmatism, (5) development of ir-
regular astigmatism, (6) loss of BSCVA.
Contact lens wearers were required to remove contact
lenses prior to the screening refraction: 3 days for soft
lenses, 1 week for soft extended wear, 2 weeks for soft toric
lenses, and 2 weeks for rigid gas permeable lenses.
Patients were excluded from the study if they met any
of the following criteria: (1) ocular condition in eyes
treated by CXL that could require additional treatment
and predispose the eye to complications, (2) clinically
significant corneal scarring unrelated to CXL, (3) chem-
ical injury to the eye treated by CXL, (4) patients with a
current condition that interferes with or prolongs epi-
thelial healing, (5) previous CXL treatment in either eye
(fellow eye was not excluded if first eye was crosslinked
as part of this study).
The subjects were recruited at The Edward S. Harkness
Eye Institute at Columbia University in New York, NY.
Thirty-seven eyes of 33 patients were crosslinked with
MedioCROSS® riboflavin/dextran solution from Septem-
ber 2010 to January 2014 (Avedro, Inc., Waltham, MA,
United States). Nineteen eyes of 19 patients were cross-
linked with Peschke® M riboflavin/HPMC solution from
January 2014 to August 2015 (Peschke Trade, Hunenberg,
Switzerland). This transition to an HPMC-based solution
was made due to a reported increase in penetration of
riboflavin into the corneal stroma with the HPMC-based
solution and the ease of use of this less viscous solution10.
Intervention
This study employed an epithelium-off 30-min UVA ex-
posure of 3 mW/cm2 after stromal saturation with either
riboflavin solution. All subjects were treated at The Ed-
ward S. Harkness Eye Institute at Columbia University
in New York, NY by one of three surgeons (GF, LS, ST).
An approximately 9 mm diameter epithelial debride-
ment was performed with an Amoils brush (Innovative
Excimer Solutions, Ontario, Canada). Subjects in the
dextran-treated group were treated with a MedioCROSS®
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0.1% riboflavin, 20% dextran 500 solution. Subjects in
the HPMC-treated solution were treated with a Peschke®
M solution containing 0.1% riboflavin and 1.1% HPMC.
Riboflavin solutions were then applied every 3 min for
30 min. Subsequently, all subjects were treated for
30 min with a UV-X™ Version 1000 light source from
IROC with 365 nm UVA light with a beam diameter of
9 mm and an irradiance of 3 mW/cm2 (IROC Innocross
AG, Zug, Switzerland). The respective riboflavin solu-
tions were applied every 3 min during the 30 min of UV
light exposure. Intraoperatively, the cornea was main-
tained at a thickness > 400 μm by measuring pachymetry
at multiple timepoints. If found to be < 400 μm, a hypo-
tonic HPMC-based riboflavin solution was applied to
swell the cornea to > 400 μm.
Patients were managed post-operatively with place-
ment of a bandage soft contact lens with topical antibi-
otics and topical steroids. The bandage contact lens was
removed and the topical antibiotic discontinued when
the epithelium was fully healed. Topical steroids were ta-
pered off over a course of 1 month.
Evaluations
Pre-op baseline exam was performed as well as follow-up
eye exams at 1 week, 1 month, 3 months, 6 months, and
every 6 months thereafter consisted of: (1) uncorrected
distance visual acuity (UCVA) (2) best spectacle-corrected
visual acuity (BSCVA), (3) manifest refraction, (4) Penta-
cam tomography measurements, (5) intraocular pressure,
and (6) slit lamp exam of cornea, anterior chamber, and
lens.
Data collection
A spreadsheet was made from the data collected from
examinations during a retrospective chart review. Chart
review was individually performed by two of the authors
(PR and PM), and all discordant values were compared
and agreed upon for the final dataset. All Pentacam
scans were reviewed for every patient to ensure adequate
Pentacam reported data quality. When multiple scans
were available for a single visit, the scan with the best
Pentacam reported data quality was selected. When mul-
tiple reliable scans or exclusively unreliable scans were
available for a single visit, the scan with the median
Kmax value was selected for each eye.
Statistical analysis
Group differences in baseline characteristics were assessed
using the student’s t-test for normally-distributed continu-
ous variables and chi-squared test for categorical variables.
The main outcome variables of interest (BSCVA, Kmax)
at 1, 6, 12, and 24 months were compared in the eyes
treated with dextran versus those treated with HPMC
using student’s t-test. The difference in BSCVA and Kmax
between the treated eye and fellow eye was calculated for
both the dextran and HPMC groups, and were compared
in the dextran versus HPMC group using paired t-test.
Results
A total of 56 eyes of 51 patients underwent CXL be-
tween September 2010 and August 2015. Thirty-seven
eyes of 33 patients were treated with a dextran-based
riboflavin solution, and 19 eyes of 19 patients were
treated with an HPMC-based riboflavin solution.
Baseline characteristics of the dextran and HPMC
groups are summarized in Table 1. There were no sig-
nificant differences in baseline or demographic charac-
teristics between the treatment groups (p > 0.05 for all).
Data comparing treatment groups are reported in Table
2 and data comparing each group to fellow eye controls
are reported in Table 3.
There were significant differences in log of the mini-
mum angle of resolution (logMAR) BSCVA in the
dextran-treated group compared with the HPMC-treated
group at 1 month (− 0.05 vs. 0.16, p < 0.001, n = 30 vs. 17),
6 months (− 0.13 vs. 0.00, p < 0.05, n = 27 vs. 15), and
24 months (− 0.18 vs. -0.01, p < 0.05, n = 15 vs. 9); the dif-
ference at 12 months was not statistically significant (−
0.16 vs. -0.03, p = 0.07, n = 20 vs. 15). The dextran-treated
group showed a significant improvement in logMAR
BSCVA compared to fellow eye controls at 6 months (−
0.13 vs. 0.00, p < 0.01, n = 22), 12 months (− 0.16 vs. 0.00,
p < 0.01, n = 19), and 24 months (− 0.19 vs. 0.00, p < 0.01,
n = 10). However, in the HPMC-treated group there was a
significant decrease in BSCVA compared to fellow eye
controls at 1 month (0.18 vs. 0.01, p < 0.01, n = 12), and no
difference at 6 months (− 0.02 vs. -0.04, p = 0.72, n = 14),
12 months (− 0.05 vs. -0.02, p = 0.65, n = 14), or 24 months
(− 0.03 vs. -0.03, p = 0.99, n = 8).
The dextran-treated group showed a significant de-
crease in Kmax compared to the HPMC-treated group at
1 month (0.12 vs. 3.32 diopter (D), p = 0.01, n = 25, 11);
however, there was no significant difference at 6 months
(− 1.29 vs. -0.20 D, p = 0.29, n = 24, 12), 12 months (− 2.41
vs. -0.45 D, p = 0.33, n = 16, 11), or 24 months (− 1.45 vs.
-1.82, p = 0.78, n = 11, 9). There was no significant change
in Kmax in the dextran-treated group when compared to
fellow eye controls at 1 month (0.34 vs. 0.39, p = 0.95, n =
16), 6 months (− 1.25 vs. 0.24, p = 0.17, n = 16), or
12 months (− 2.19 vs. -0.42 D, p = 0.38, n = 13). There was
no significant change in Kmax in the HPMC-treated
group when compared to fellow eye controls at 1 month
(4.9 vs. -0.4 D, p = 0.08, n = 6) or 6 months (− 0.27 vs. 0.81
D, p = 0.13, n = 9); however, there was a significant
decrease in Kmax in the HPMC-treated group compared
to fellow eye controls at 12 months (− 0.88 vs. 1.13 D, p =
0.02, n = 9).
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This retrospective analysis of corneal crosslinking clin-
ical outcomes showed better visual acuity results with a
dextran-based riboflavin solution as compared to an
HPMC-based riboflavin solution. BSCVA was improved
by 1 month in the dextran-treated group and this im-
provement is seen also at 6 months and at 24 months,
while mean BSCVA in the HPMC-treated group did not
improve.
The dextran-treated group showed an advantage over
the HPMC-treated group in measurement of Kmax at
1 month. The dextran-treated group had a stable Kmax
at 1 month, whereas the HPMC-treated group had an
increase in Kmax at 1 month, although this increase was
not statistically significant when compared to fellow eye
controls. There was no significant difference in the
change in Kmax between the HPMC and dextran treat-
ment groups at 6, 12, and 24 months. The HPMC group
showed a statistically significant decrease in Kmax com-
pared to fellow-eye controls at 12 months whereas the
dextran group did not; however, this decrease in Kmax
in the HPMC group did not correlate with visual
improvement.
Discussion
This introductory study is the first to demonstrate differ-
ences in visual outcomes up to 2 years after CXL be-
tween isotonic HPMC and dextran-based riboflavin
solutions and provides justification for further investiga-
tion into the differences between CXL with different solu-
tions. The improvements in visual acuity demonstrated in
this study after CXL are consistent with the current litera-
ture, as a recent systematic review and meta-analysis has
found improvements in BSCVA as early as 3 months after
crosslinking [5]. Additionally, prior studies comparing vis-
ual outcomes after CXL between dextran-based riboflavin
solutions and hypotonic HPMC-based riboflavin solutions
have seen a statistically significant improvement in vision
with dextran compared to hypotonic HPMC at 1 year
[14]. These data show that although Kmax results after
CXL are comparable with these solutions, the visual out-
comes are better with dextran solutions than with HPMC
solutions. Further investigation with more data is required
to better understand the connection between BSCVA and
Kmax in patients after CXL.
One potential explanation for the difference in out-
comes is a differential penetration of UV light into the
corneal stroma between the two solutions. It has been
shown that dextran-based riboflavin solutions signifi-
cantly thin the cornea and isotonic HPMC-based ribofla-
vin solutions have little impact on corneal thickness and
may slightly swell or slightly thin the cornea during CXL
[10, 11]. Recent studies have shown that a 20% dextran
0.1% riboflavin solution with a 30-min induction period
allows UV light to penetrate a greater percentage of the
corneal stroma than does a 1.1% HPMC 0.1% riboflavin
solution even with a 10-min induction [15]. The differ-
ence in the depth of penetration only increases when the
induction time for the HPMC-based riboflavin solution
was increased to 30 min. In addition to allowing for a
Table 1 Baseline characteristics of subjects by treatment group
HPMC-treated Dextran-treated p
(n = 19) (n = 37)
Age, years 26.7 ± 8.2 30.8 ± 10.3 0.12
Male, n (%) 15 (78.9) 29 (78.4) 0.63
Post-Lasik Ectasia, n (%) 1 (5.2) 9 (24.3) 0.08
Keratoconus, n (%) 18 (94.8) 28 (75.7) 0.08
BCVA preoperative (treated eye), logMAR 0.21 ± 0.17 0.31 ± 0.24 0.11
BCVA preoperative (control eye), logMAR 0.10 ± 0.16 0.07 ± 0.16 0.45
Kmax preoperative (treated eye), diopters 61.1 ± 8.7 57.7 ± 8.1 0.17
Kmax preoperative (control eye), diopters 51.0 ± 3.7 51.0 ± 6.7 0.98
BCVA= best corrected visual acuity, HPMC= hydroxypropyl methylcellulose
Table 2 Comparison of BSCVA and Kmax between HPMC vs.
Dextran-treated Groups
HPMC Group Dextran Group
Mean n-value Mean n-value p-value
Change in BSCVA (SD)
1 Month 0.16 (0.15) 17 −0.05 (0.20) 30 < 0.001
6 Months 0.00 (0.17) 15 − 0.13 (0.17) 27 < 0.05
12 Months −0.03 (0.16) 15 −0.16 (0.22) 20 0.07
24 Months −0.01 (0.13) 9 −0.18 (0.17) 15 < 0.05
Change in Kmax (SD)
1 Month 3.32 (4.89) 11 0.12 (2.23) 25 < 0.05
6 Months −0.20 (2.22) 12 −1.29 (3.12) 24 0.29
12 Months −0.45 (2.35) 11 −2.41 (6.21) 16 0.33
24 Months −1.82 (3.38) 9 −1.45 (2.65) 11 0.78
bolded values represent statistical significance
BSCVA= best spectacle corrected visual acuity, HPMC= hydroxypropyl
methylcellulose, SD= standard deviation
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greater percentage depth of UV light penetration, the
transient thinning of the cornea with the use of 20%
dextran is likely to result in a significantly greater depth
of post-operative cornea treated with UV light once the
dextran-thinned cornea returns to its pre-operative
thickness.
The depth of penetration of the UV light will likely
correlate with the demarcation line visible after CXL.
The demarcation line has been suggested as an objective
marker to determine the efficacy of corneal crosslinking
and increasing depth of demarcation line has been asso-
ciated with improved Kmax outcomes [16]. In contrast,
others in the crosslinking field question the paradigm of
“the deeper, the better” regarding demarcation line [17].
A recent study reporting on demarcation line depth in
contact lens-assisted CXL finds a deeper demarcation
line with isotonic 1.1% HPMC than with the standard
20% dextran solution, although these authors do not as-
sert that a deeper demarcation line represents a desir-
able outcome [18].
In the future, we would like to see isotonic HPMC and
dextran-based riboflavin solutions compared in a large
prospective randomized trial to determine whether the
differences in clinical outcomes are truly clinically sig-
nificant. Ideally, we would have anterior segment optical
coherence tomography (OCT) data for these patients in
order to compare the depth of the demarcation line in
the two treatment groups to determine whether a deeper
demarcation line is associated with improved clinical
outcomes. Additionally, in future studies we would have
Pentacam densitometry data in order to formally grade
stromal haze and to correlate postoperative haze and vis-
ual acuity after CXL with HPMC and dextran-based
riboflavin solutions.
There are some limitations to our retrospective study.
First, there is a small number of patients in each group,
which decreases by the first year of follow up. The small
number of patients limited our ability to compare differ-
ences in crosslinking outcomes between patients with
keratoconus and post-refractive surgery ectasia. How-
ever, we performed our study in a controlled environ-
ment with the same treatment and follow-up protocol.
Although the number of patients is relatively small, we
believe that the results of our study justify the need for
higher-powered studies in the future. Secondly, kerato-
conus is a bilateral disease, therefore the “control” eye
likely has a degree of corneal ectasia as well, which may
affect the results. However, we believe that it is import-
ant to compare the treated eye with the fellow eye to
demonstrate halting the disease. Thirdly, we have in-
cluded patients with KCN and post-LASIK ectasia in
this study, which are two distinct disease processes, and
Table 3 Changes in BSCVA and Kmax between Treatment Groups vs. Fellow Eye Controls
HPMC Treatment Eye Control Eye
Mean Change in BSCVA (SD) Mean Mean n value** p-value
1 Month 0.18 (0.17) 0.01 (0.06) 12 < 0.05
6 Months − 0.02 (0.16) − 0.04 (0.09) 14 0.72
12 Months − 0.05 (0.15) − 0.02 (0.08) 14 0.65
24 Months − 0.03 (0.13) − 0.03 (0.08) 8 0.99
Mean Change in Kmax (SD)
1 Month 4.9 (5.89) −0.40 (2.93) 6 0.08
6 Months −0.27 (2.13) 0.81 (1.14) 9 0.13
12 Months −0.88 (2.18) 1.13 (1.74) 9 < 0.05
Dextran Treatment Eye Control Eye
Mean Change in BSCVA (SD) Mean Mean n value p-value
1 Month −0.03 (0.20) − 0.02 (0.11) 26 0.74
6 Months −0.13 (0.18) 0.00 (0.08) 22 < 0.01
12 Months −0.16 (0.22) 0.00 (0.10) 19 < 0.01
24 Months −0.19 (0.17) 0.00 (0.08) 10 < 0.01
Mean Change in Kmax (SD)
1 Month 0.34 (1.88) 0.39 (0.81) 16 0.95
6 Months − 1.25 (3.67) 0.24 (0.96) 16 0.17
12 Months −2.19 (6.84) −0.42 (1.09) 13 0.38
bolded values represent statistical significance
**number of patients is less than Table 2 due to incomplete data availability
BSCVA= best spectacle corrected visual acuity, HPMC= hydroxypropyl methylcellulose, SD= standard deviation
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analyzed the results of CXL in these patients in a single
group. Finally, this study does not include anterior OCT
data or Pentacam densitometry data for correlation of
stromal haze with visual acuity. We hope future CXL tri-
als will look more closely at this relationship given the
differences in visual acuity shown in this study.
Conclusions
In conclusion, this study is the first to describe differ-
ences in outcomes of epithelium-off corneal collagen
crosslinking between different isotonic riboflavin solu-
tions. In the past, many studies have looked at differ-
ences in UV exposure times and method of entry for
riboflavin solutions into the corneal stroma. By effect-
ively comparing the different isotonic riboflavin solu-
tions, a more efficient method of epithelium-off corneal
collagen crosslinking can be determined for future
treatments.
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